Consultation: PMPRB Draft Guidelines

The Patented Medicines Regulations were recently amended, to allow the PMPRB to identify gross and net non-excessive ceiling prices of patented medicines in Canada that are more closely aligned with prices in like-minded countries, more reflective of their value to Canadian consumers and more informed by the affordability constraints of the Canadian economy. Changes in the Draft Guidelines are necessary to operationalize the regulatory amendments.

The draft guidelines are currently open for consultation, and CSHP will be preparing a response. 

Please review the draft guidelines and backgrounder here and provide your feedback to Christina Adams, Chief Pharmacy Officer, by January 20th 2020.